Human Genome Sciences, located in Rockville, MD, is an independent biopharmaceutical company that specializes in the development and commercialization of innovative therapies for various medical conditions. Their flagship product, BENLYSTA, is a prescription medicine used to treat active systemic lupus erythematosus (SLE) and lupus nephritis, a kidney inflammation associated with lupus. BENLYSTA works by targeting the underlying causes of lupus and has been studied extensively in diverse patient populations, demonstrating a consistent safety profile.
With a focus on reducing lupus disease activity and improving the immune system, muscles, joints, mouth, and skin, BENLYSTA is taken in addition to other lupus medications. The company's commitment to patient support is evident through personalized resources, helpful guides, and real patient experiences shared to provide valuable insights. Human Genome Sciences is dedicated to advancing the treatment options available for individuals living with lupus and lupus-related conditions.
Generated from the website